News
XyloCor Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiovascular disease, announced the first patient has been dosed in the Phase 2b EXACT-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback